

New CD19 and BCMA Data to be Presented at the Society for Immunotherapy of Cancer Annual Meeting

HAMILTON, Ontario and HACKENSACK, NJ – November 10, 2016 – Triumvira Immunologics today announced that new data on the TAC platform will be presented Friday, November 11 at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland.



Dr. Chris Helsen, Triumvira's Head of Platform Development, is presenting a poster (P18) entitled "T cell antigen couplers (TAC) demonstrate strong effectivity against solid tumors with no measurable toxicities, demonstrating an enhanced therapeutic index" which will include animal data from our solid tumor HER2 TAC-T cell program and new animal data from our CD19 and BCMA programs, demonstrating robust anti-tumor activity for both. An additional poster (P16), supported in part with funding from Triumvira, entitled "A novel xenograft model of chimeric antigen receptor-mediated toxicity sheds light on the influence of T cell source on the severity of the toxic sequelae" details the toxicity profile of HER2 CAR-T cells in mice, which contrasts sharply with the safety profile observed for HER2 TAC-T cells.

Jonathan Bramson, PhD, Triumvira's Chief Scientific Officer, commented "We are pleased to have the opportunity to present new results from several programs at the SITC Annual Meeting. In particular, the results we have seen with CD19 and BCMA directed TAC-T cells give us great confidence in these two programs as we move them forward to the clinic."

The SITC is the world's leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. The SITC's Annual Meeting provides a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.

About Triumvira Immunologics Inc.

Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to attack cancers. Triumvira's innovative and proprietary technology for reprogramming T cells, called the T Cell-Antigen Coupler (or TAC), may possess advantages over other approaches to engineered T cells owing to the distinct biology and regulated activation of TAC-T cells. Triumvira has licensed the TAC technology from McMaster University in Hamilton, Ontario and its goal is to begin human testing of TAC T cells in early 2018.

Contact

Triumvira Immunologics Inc.
175 Longwood Road South, Suite 305
Hamilton, Ontario L8P 0A1, Canada
Phone: 1-201-882-4550
Email: info@triumvira.com